Zealand Pharma to Participate in 21st Annual Needham Virtual Healthcare Conference

Apr 4th, 2022 8:30 EST

Company announcement – No. 11 / 2022

Zealand Pharma to Participate in 21st Annual Needham Virtual Healthcare Conference

Copenhagen, DK and Boston, MA, U.S. April 4, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Chief Executive Officer Adam Steensberg and Chief Financial Officer Matthew Dallas are scheduled to participate in the 21st Annual Needham Virtual Healthcare Conference:

21st Annual Needham Virtual Healthcare Conference Date: Monday, April 11, 2022Presentation: 9:30 a.m. EST / 2:30 p.m. GMT / 3:30 p.m. CET

A live webcast of the event will be available on the “Events & Presentations” page in the Investor section of the Company’s website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company’s website following the presentation.

# # #

About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

For further information, please contact:

Zealand Pharma Investor RelationsMaeve ConneightonArgot Partners[email protected]

Zealand Pharma Media Relations David Rosen Argot Partners[email protected]

Link to Source

Leave a Comment

SOTD Membership

Register by Email

or
Already a member? Sign In